Charts

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest ...

MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on Thursday, February 9, 2023, at 1:35 p.m. EST in New York. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors

– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –MOUNTAIN VIEW, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-7354, a targeted IL-15/IL-15R IgM antibody which could potentially be used for the treatment of patients with so

Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a ...

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in ...

In trading on Wednesday, shares of IGM Biosciences Inc (IGMS) crossed above their 200 day moving average of $19.38, changing hands as high as $20.55 per share. IGM Biosciences Inc shares are currently trading up about 7.3% on the day..

– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI chemotherapy – – Randomized combination trial in second-line colorectal cancer patients to initiate in Q1 2023 – MOUNTAIN VIEW, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today

MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Com

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $40.26 per unit.

First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster PresentationsMOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM’s expanding portfolio of T cell engagers for hematologic malignancies, including IGM-2644, IGM-2537 and imvotamab, at the 2022 American Society of Hematology (ASH) Annual Meeting and E

MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” sectio

According to data from Benzinga Pro, during Q3, IGM Biosciences's (NASDAQ:IGMS) reported sales totaled $331 thousand. Despite a 0.95% ...

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. Elevate Credit, Inc. (NYSE: ELVT) ...

Those following along with IGM Biosciences, Inc. ( NASDAQ:IGMS ) will no doubt be intrigued by the recent purchase of...

U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks ...

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the ...

Although US stocks closed sharply higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast ...

MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 15 at 9:45 a.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 17 at 9:45 a.m. GMT/ 4:45 a.m. EST i

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting – – Data Update from Phase 1 Trial of Imvotamab Demonstrates Durable Benefit for R/R NHL Patients, with 7/8 Complete Response Patients Tumor Free After 1 Year – MOUNTAIN VIEW, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creati

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate the combination of imvotamab, IGM’s novel IgM CD20 x CD3 T cell engaging bispecific antibody, and ZYNLONTA® (loncastuximab tesirine-lpyl), ADC Therapeutics’ CD19-directed antibody drug conjugate (ADC), for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma (NHL).

– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUNTAIN VIEW, Calif. and LAUSANNE, Switzerland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they ha

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $210.25 per unit.

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

In trading on Thursday, shares of IGM Biosciences Inc (IGMS) crossed below their 200 day moving average of $18.99, changing hands as low as $18.22 per share. IGM Biosciences Inc shares are currently trading down about 6.7% on the day..

Upgrades For Citi Trends Inc (NASDAQ:CTRN), Gordon Haskett upgraded the previous rating of Reduce to Hold. For the second quarter, ...

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. SAI.TECH Global Corporation (NASDAQ: SAI) gained 43.4% ...

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional ...

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording ...

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $215.13 per unit.

Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second ...

In trading on Wednesday, shares of IGM Biosciences Inc (IGMS) crossed above their 200 day moving average of $25.24, changing hands as high as $26.00 per share. IGM Biosciences Inc shares are currently trading up about 11% on the day..

IGM Biosciences (NASDAQ:IGMS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:10 PM. Here's what ...

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing of Collaboration Agreement with Sanofi – MOUNTAIN VIEW, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent develo

In the last year, multiple insiders have substantially increased their holdings of IGM Biosciences, Inc. ( NASDAQ:IGMS...

Looking back to 93 days ago, IGM Biosciences Inc (IGMS) priced a 8,695,653 share secondary stock offering at $23.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

MOUNTAIN VIEW, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 3:00 p.m. EST in New York. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of t

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in IGM Biosciences Inc (IGMS), where a total of 2,206 contracts have traded so far, representing approximately 220,600 underlying shares. That amounts to about 52% of IGMS's average daily trading volume over the past month of 424,260 shares..

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

In trading on Thursday, shares of IGM Biosciences Inc (IGMS) touched a new 52-week low of $12.74/share. That's a $86.70 share price drop, or -87.19% decline from the 52-week high of $99.44 set back on 06/07/2021..

MOUNTAIN VIEW, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 9:30 a.m. EST in New York. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors

– Closing of Global Collaboration Agreement with Sanofi; $150 Million Upfront Payment to IGM – – Completed Public Equity Offering with Gross Proceeds of $230 Million – – Continued Advancement in Clinical Development of IGM-2323 and IGM-8444 – MOUNTAIN VIEW, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the first quarter ended March 3

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IGM Biosciences Inc (IGMS), where a total volume of 2,044 contracts has been traded thus far today, a contract volume which is representative of approximately 204,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.9% of IGMS's average daily trading volume over the past month, of 352,815 shares..

$150 Million Payment to IGM from SanofiMOUNTAIN VIEW, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), has expired in connection with the Company’s previously announced exclusive worldwide collaboration agreement with Sanofi. In connection

Gainers Better Therapeutics (NASDAQ:BTTX) stock increased by 9.9% to $2.21 during Monday's after-market session. Today's trading ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $42.56 per unit.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! Another day of trading lies ahead and we're starting it off with the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Looking back to 2 days ago, IGM Biosciences Inc (IGMS) priced a 8,695,653 share secondary stock offering at $23.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Truist haslowered the price targetonIGM Biosciences Inc(NASDAQ: IGMS) to $74 from $80. The analyst Asthika ...

Morgan Stanley raised the price target on IGM Biosciences, Inc. (NASDAQ: IGMS) from $25 to $30. IGM Biosciences shares fell 4% to ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J, ViiV Co-developed ...

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM ...

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here are the various catalysts investors in IGM Biosciences and IGMS stock are watching today as shares more than double. The post Why Is IGM Biosciences (IGMS) Stock Up Today? appeared first on InvestorPlace. More From InvestorPlace Get in Now on Tiny $3 ‘Forever Battery’ Stock It doesn’t matter if you have $500 in savings or $5 million. Do this now. Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IGM Biosciences Inc (IGMS), where a total volume of 21,227 contracts has been traded thus far today, a contract volume which is representative of approximately 2.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 735.5% of IGMS's average daily trading volume over the past month, of 288,590 shares..

U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday. The Dow traded up 0.73% to ...

Gainers IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM ...

Optimism is high on Wall Street, as peace talks between Ukraine and Russia seem to advance.

U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday. The Dow traded up 0.75% to ...

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: ...

In addition to reporting its fourth-quarter results, the clinical-stage biotech announced a lucrative new collaboration deal with Sanofi.

U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning. The Dow traded up 1.02% to ...

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The ...

Upward momentum on Wall Street continued.